---
input_text: "Safety outcomes and patients' preferences for home-based intravenous
  enzyme replacement therapy (ERT) in pompe disease and mucopolysaccharidosis type
  I (MPS I) disorder: COVID-19 and beyond. BACKGROUND: The Italian Medicines Agency
  (AIFA) demands precise information on benefit/risk profile of home-based enzyme
  replacement therapy (ERT) for the treatment of patients with Pompe disease and Mucopolysaccharidosis
  type I (MPS I). This passage is necessary to obtain the authorization for ERT home
  therapy, even after the coronavirus disease-19 (COVID-19) pandemic period. This
  research intends to evaluate the safety, treatment satisfaction, and compliance
  of MPS I patients treated with laronidase (Aldurazyme ) and Pompe Disease patients
  treated with alglucosidase alfa (Myozyme ) in a homecare setting. RESULTS: We report
  herein an early interim analysis of the HomERT (Home infusions of ERT) study, a
  multicenter, non-interventional, double-cohort study that retrospectively analyzed
  38 patients from 14 sites in Italy: cohort A (Pompe disease - 32 patients) and cohort
  B (MPS I - 6 patients). Among the selected patients who started home therapy before
  enrollment, the average number of missed home-based infusions was 0.7 (1.3) in cohort
  A and 3.8 (6.4) in cohort B with no return to the hospital setting. Irrespective
  of the treatment location, 3 prior ADRs per cohort were reported. The majority of
  patients preferred home-based infusions (cohort A: 96.9%; cohort B: 100%): the main
  reason was attributed to treatment convenience (cohort A: 81.3%; cohort B: 83.3%).
  Despite the underlying conditions, most patients self-evaluated their health as
  \"good\" (cohort A: 50%; cohort B: 83.3%). CONCLUSIONS: Evidence of favorable safety
  profile, improved treatment compliance and personal satisfaction validates the use
  of ERT with laronidase and alglucosidase alfa as a strong candidate for home therapy."
raw_completion_output: |-
  primary_disease: Pompe disease; Mucopolysaccharidosis type I (MPS I)
  medical_actions: home-based intravenous enzyme replacement therapy (ERT); self-evaluated health assessment
  symptoms: missed home-based infusions; adverse drug reactions (ADRs)
  chemicals: laronidase; alglucosidase alfa
  action_annotation_relationships: home-based intravenous enzyme replacement therapy (ERT) PREVENTS missed home-based infusions IN Pompe disease; home-based intravenous enzyme replacement therapy (ERT) PREVENTS missed home-based infusions IN Mucopolysaccharidosis type I (MPS I); self-evaluated health assessment TREATS subjective health perception IN Pompe disease; self-evaluated health assessment TREATS subjective health perception IN Mucopolysaccharidosis type I (MPS I); enzyme replacement therapy (with laronidase) PREVENTS adverse drug reactions (ADRs) IN Mucopolysaccharidosis type I (MPS I); enzyme replacement therapy (with alglucosidase alfa) PREVENTS adverse drug reactions (ADRs) IN Pompe disease
prompt: |+
  From the text below, extract the following entities in the following format:

  subject_extension: <A chemical or drug mentioned in the relationship between the medical action and the symptom, for example, "analgesic agent therapy" has the aspect "analgesic">
  object_extension: <An optional term describing some specific aspect of the object, e.g. "analgesic agent therapy" has the aspect "analgesic">
  subject: <The medical action. For example: blood transfusion, radiation therapy, cardiac catheterization, pulse oximetry, otoscopy>
  predicate: <The relationship type between the medical action and the symptom, usually TREATS or PREVENTS.>
  object: <A sign or symptom associated with the disease and targeted by the medical action. For example, Low serum calcitriol, hypoplasia of the thymus, chronic cough, aortic stiffness, low pulse pressure>
  qualifier: <The primary disease the relationship is about, or specifically the disease the symptom is related to. For example, Beck-Fahrner syndrome, hereditary retinoblastoma, progeria, diabetes mellitus, infectious otitis media>
  subject_qualifier: <An optional qualifier or modifier for the subject of the statement, e.g. "high dose" or "intravenously administered">
  object_qualifier: <An optional qualifier or modifier for the object of the statement, e.g. "severe" or "with additional complications">


  Text:
  enzyme replacement therapy (with alglucosidase alfa) PREVENTS adverse drug reactions (ADRs) IN Pompe disease

  ===

extracted_object:
  primary_disease: MONDO:1012617
  medical_actions:
    - home-based intravenous enzyme replacement therapy (ERT)
    - self-evaluated health assessment
  symptoms:
    - missed home-based infusions
    - HP:0020172
  chemicals:
    - laronidase
    - alglucosidase alfa
  action_annotation_relationships:
    - subject: home-based intravenous enzyme replacement therapy
      predicate: PREVENTS
      object: missed home-based infusions
      qualifier: MONDO:0009290
      subject_qualifier: home-based intravenous
      subject_extension: enzyme replacement therapy (ERT)
    - subject: home-based intravenous enzyme replacement therapy
      predicate: PREVENTS
      object: missed home-based infusions
      qualifier: MONDO:0001586
      subject_qualifier: home-based intravenous
      subject_extension: enzyme replacement therapy
      object_extension: missed home-based infusions
    - subject: self-evaluated health assessment
      predicate: TREATS
      object: subjective health perception
      qualifier: MONDO:0009290
    - subject: self-evaluated health assessment
      predicate: TREATS
      object: subjective health perception
      qualifier: MONDO:1012617
    - subject: enzyme replacement therapy
      predicate: PREVENTS
      object: HP:0020172
      qualifier: MONDO:1012617
      subject_qualifier: with laronidase
      subject_extension: laronidase
    - subject: enzyme replacement therapy
      predicate: PREVENTS
      object: HP:0020172
      qualifier: MONDO:0009290
      subject_qualifier: with alglucosidase alfa
      subject_extension: alglucosidase alfa
named_entities:
  - id: MONDO:0001586
    label: mucopolysaccharidosis type I
  - id: MONDO:1012617
    label: Mucopolysaccharidosis Type I (MPS I)
  - id: CHEBI:60285
    label: DOPE
  - id: MAXO:0001521
    label: nasal administration
  - id: MONDO:0011758
    label: Mucopolysaccharidosis type I Hurler (MPSIH)
  - id: MAXO:0000747
    label: hematopoietic stem cell transplantation (HSCT)
  - id: MAXO:0000487
    label: clinical assessment (growth measurement, kyphosis and genu velgum evaluation)
  - id: HP:0002808
    label: kyphosis
  - id: HP:0001376
    label: limited joint mobility
  - id: HP:0008807
    label: acetabular dysplasia
  - id: MAXO:0010034
    label: Corneal transplantation
  - id: HP:0007957
    label: Corneal clouding
  - id: MAXO:0000149
    label: Hematopoietic cell transplantation (HCT)
  - id: HP:0000238
    label: Hydrocephalus
  - id: MAXO:0000068
    label: transplantation
  - id: MAXO:0000004
    label: surgery
  - id: MAXO:0000526
    label: clinical examination
  - id: CHEBI:143889
    label: glycosaminoglycan (GAG)
  - id: HP:0004322
    label: short stature
  - id: HP:0005619
    label: thoracolumbar kyphosis
  - id: HP:0000943
    label: dysostosis multiplex
  - id: MONDO:0011759
    label: Hurler-Scheie syndrome
  - id: HP:0001387
    label: joint stiffness
  - id: HP:0000403
    label: recurrent otitis media
  - id: HP:0001999
    label: facial dysmorphism
  - id: HP:0002781
    label: Upper airway obstruction
  - id: HP:0001638
    label: Cardiomyopathy
  - id: MAXO:0001479
    label: Allogeneic hematopoietic stem cell transplantation
  - id: MAXO:0001001
    label: Gene therapy
  - id: CHEBI:58187
    label: Alginate
  - id: CHEBI:53412
    label: PLL (Poly-L-lysine)
  - id: CHEBI:50594
    label: Carbon nanotubes
  - id: HP:0007663
    label: Reduced visual acuity
  - id: MAXO:0000016
    label: cellular therapy
  - id: CHEBI:19226
    label: Tm
  - id: MONDO:0017385
    label: mucopolysaccharidosis type I (MPSI) Hurler
  - id: MAXO:0000018
    label: Biomarker assessment
  - id: HP:0001138
    label: Optic neuropathy
  - id: HP:0000488
    label: Retinopathy
  - id: MONDO:0019052
    label: Inborn errors of metabolism
  - id: CHEBI:28901
    label: Busulfan
  - id: CHEBI:33310
    label: MCT (NE)
  - id: HP:0001367
    label: joint disease
  - id: HP:0002652
    label: skeletal dysplasia
  - id: HP:0000618
    label: vision impairments
  - id: HP:0000365
    label: hearing impairments
  - id: MONDO:0007147
    label: Obstructive sleep apnea syndrome (OSAS)
  - id: MAXO:0000915
    label: Overnight polysomnography (PSG)
  - id: HP:0002104
    label: Apnea
  - id: HP:0040213
    label: Hypopnea
  - id: MAXO:0010033
    label: Umbilical cord blood transplantation
  - id: MONDO:0009290
    label: Pompe Disease
  - id: HP:0005162
    label: Left ventricular failure
  - id: HP:0011675
    label: Conduction abnormalities
  - id: HP:0001677
    label: Coronary artery disease
  - id: HP:0001433
    label: Hepatosplenomegaly
  - id: HP:0033126
    label: Necrosis
  - id: CHEBI:46793
    label: 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-(amino[polyethylene glycol]-
      2000) (DSPE-PEG)
  - id: CHEBI:17754
    label: Glycerol
  - id: CHEBI:15377
    label: Water
  - id: CHEBI:27881
    label: Resveratrol
  - id: HP:0010864
    label: severe mental retardation
  - id: CHEBI:82467
    label: Evans blue
  - id: MONDO:0006249
    label: mucopolysaccharidoses (MPS)
  - id: CHEBI:232920
    label: Alginate-poly-L-lysine-alginate (APA)
  - id: HP:0000708
    label: Behavioral abnormalities
  - id: HP:0033429
    label: Neuroinflammation
  - id: MAXO:0001525
    label: Intravenous administration
  - id: HP:6000847
    label: cardiac mass
  - id: HP:0012393
    label: Allergic reactions
  - id: HP:0001268
    label: Cognitive decline
  - id: HP:0000388
    label: Otitis media
  - id: HP:0000750
    label: Language delays
  - id: MAXO:0000479
    label: Orthopedic surgeries
  - id: HP:0011947
    label: Respiratory infections
  - id: CHEBI:28088
    label: Genistein
  - id: MAXO:0000506
    label: Non-invasive ventilation
  - id: HP:0002091
    label: Restrictive lung disease
  - id: HP:0001513
    label: Obesity
  - id: HP:0000822
    label: High blood pressure
  - id: HP:0001626
    label: Cardiovascular abnormalities
  - id: CHEBI:18376
    label: dermatan sulfate
  - id: CHEBI:28815
    label: heparan sulfate
  - id: CHEBI:37397
    label: chondroitin sulfate
  - id: CHEBI:15971
    label: heparan sulfate (HS)
  - id: CHEBI:17053
    label: dermatan sulfate (DS)
  - id: CHEBI:16991
    label: DNA
  - id: HP:0001385
    label: Hip dysplasia
  - id: HP:0001263
    label: Cognitive delay
  - id: CHEBI:50693
    label: Milrinone
  - id: MAXO:0000011
    label: Physical therapy
  - id: HP:0003423
    label: Thoracolumbar kyphoscoliosis
  - id: HP:0002970
    label: Genua vara
  - id: HP:0002650
    label: Scoliosis
  - id: HP:0002857
    label: Genua valga
  - id: HP:0003311
    label: Odontoid hypoplasia
  - id: HP:0100543
    label: cognitive impairment
  - id: HP:0002180
    label: neurodegeneration
  - id: CHEBI:50803
    label: nanoparticles
  - id: HP:0002176
    label: spinal cord compression
  - id: HP:0012531
    label: pain (injection site, back, groin)
  - id: HP:0002315
    label: headache
  - id: HP:0033482
    label: limited shoulder flexion
  - id: HP:0004349
    label: decreased bone mineral density
  - id: HP:0000924
    label: skeletal anomalies
  - id: HP:0002240
    label: hepatomegaly
  - id: HP:0010619
    label: correlation of reaction time with fractional anisotropy (FA) in frontal
      and parietal white matter
  - id: HP:0003541
    label: Urinary glycosaminoglycan (GAG) excretion
  - id: HP:0002870
    label: Obstructive sleep apnea syndrome (OSAS)
  - id: HP:0001653
    label: mitral regurgitation
  - id: HP:0001712
    label: LVH (left ventricular hypertrophy)
  - id: HP:0001655
    label: PFO (patent foramen ovale)
  - id: HP:0001250
    label: seizure
  - id: HP:0000505
    label: Visual impairment
  - id: HP:0000481
    label: corneal abnormalities
  - id: HP:0000716
    label: depression
  - id: HP:0000752
    label: hyperactivity
  - id: HP:0007018
    label: attention deficit disorder
  - id: HP:0010535
    label: Sleep apnoea
  - id: CHEBI:4439
    label: Dermatan
  - id: MONDO:0002561
    label: Lysosomal Storage Disorders (LSDs)
  - id: CHEBI:36080
    label: protein
  - id: MONDO:0016063
    label: Crohn disease (CD)
  - id: MAXO:0001184
    label: colonoscopies
  - id: CHEBI:9513
    label: thalidomide
  - id: CHEBI:64357
    label: rituximab
  - id: CHEBI:9168
    label: sirolimus
  - id: MONDO:0005011
    label: Crohn disease
  - id: MAXO:0001394
    label: Oral administration
  - id: HP:0020172
    label: adverse drug reactions (ADRs)
